Vanda Pharmaceuticals Inc. announced positive top-line results from a phase III trial showing that investigational drug candidate, tasimelteon (VEC-162), a novel melatonin agonist, met the primary endpoint of the trial and significantly improved sleep in adult patients with chronic insomnia.
We are excited that the results of this phase III chronic insomnia study demonstrate the clinical utility of tasimelteon and the ability of the compound to treat sleep disorders over a period of four weeks. The mechanism of action of tasimelteon as a circadian regulator gives Vanda the opportunity to explore its use for the treatment of circadian rhythm sleep disorders as well as chronic primary insomnia, stated Paolo Baroldi, MD, PhD, Vanda's chief medical officer.
The details can be read here.
No comments:
Post a Comment